CN Patent

CN113015521A — 用于口服的包含氨基嘧啶衍生物或其盐的药物组合物

Assigned to Yuhan Corp · Expires 2021-06-22 · 5y expired

What this patent protects

本公开提供了一种用于口服的药物组合物，该药物组合物包含：N‑(5‑(4‑(4‑((二甲基氨基)甲基)‑3‑苯基‑1H‑吡唑‑1‑基)嘧啶‑2‑基氨基)‑4‑甲氧基‑2‑吗啉代苯基)丙烯酰胺(拉泽替尼)或其药学上可接受的盐作为活性成分；以及微晶纤维素和甘露糖醇的组合作为稀释剂。

USPTO Abstract

本公开提供了一种用于口服的药物组合物，该药物组合物包含：N‑(5‑(4‑(4‑((二甲基氨基)甲基)‑3‑苯基‑1H‑吡唑‑1‑基)嘧啶‑2‑基氨基)‑4‑甲氧基‑2‑吗啉代苯基)丙烯酰胺(拉泽替尼)或其药学上可接受的盐作为活性成分；以及微晶纤维素和甘露糖醇的组合作为稀释剂。

Drugs covered by this patent

lazertinib-mesylate (LAZERTINIB MESYLATE)

Patent Metadata

Patent number: CN113015521A
Jurisdiction: CN
Classification: —
Expires: 2021-06-22
Drug substance claim: No
Drug product claim: No
Assignee: Yuhan Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.